Soligenix announces advancements in HyBryte

Soligenix is making significant strides in the treatment of Cutaneous T-Cell Lymphoma, CTCL, with its investigational drug, HyBryte. In an exclusive interview, PCG Digital speaks with Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigator for Soligenix’s comparative study, who shares insights on the promising advancements. Soligenix plans to initiate patient enrollment in the confirmatory FLASH 2 study with HyBryte by the end of 2024. The company continues to explore the potential of HyBryte in treating other dermatological conditions such as psoriasis, where it has a Phase 2 study ongoing, demonstrating its commitment to expanding treatment options for patients with skin diseases.